

Drug Use Review (DUR) Board approves changes effective June 2, 2025

The Nevada Medicaid Drug Use Review (DUR) Board met on July 18, 2024 and voted to adopt the following changes to Pharmacy Point-of-Sale (POS) criteria, effective June 2, 2025.

Drug Class/Program	Background and Explanation of Policy Changes, Clarifications and Updates
Incretin Mimetics	Additional language under Wegovy® (semaglutide) to add that the recipient has established cardiovascular (CV) disease verified by a specialist that has provided documentation.

Prior Authorization forms may be found on the pharmacy webpage:
<https://nv.primetherapeutics.com/provider/forms> (pharmacy/point-of-sale)